http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Adagene Inc. (ADAG) Presents Interim Results Reinforcing Best-in-Class Profile of ADG126
-
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colo
-
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
-
Adagene Inc. (ADAG) Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126
-
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
-
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
-
Adagene to Present at Investor and Scientific Conferences in September
-
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
-
Adagene (ADAG) Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126
-
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
-
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
-
Adagene (ADAG) Reports FY22, Provides Corporate Update
-
Adagene (ADAG) Reports FY22, Provides Corporate Update
-
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
-
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
-
Adagene Inc. (ADAG) Appoints Aurélien Marabelle to its Board
-
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
-
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
-
Adani Group shares slide further as Hindenburg row heats up
-
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
-
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
-
Adagene Inc. (ADAG) Announces Clinical Trial Collaboration for ADG126
-
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
-
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
-
Adagene Inc. (ADAG) Appoints Cuong Do to its Board
-
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
-
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
-
Adagene Inc. (ADAG) Reports Data on ADG116
-
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
-
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
-
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
-
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
-
Adagene Inc. (ADAG) Reports Strong Interim Monotherapy Data of ADG126
-
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
-
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
-
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
-
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
-
Adagene Inc. (ADAG) Announces $10M Share Buyback
-
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
-
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
-
Adagene Inc. (ADAG) Reports Publication of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of ADG126,
-
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
-
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
-
Adagene to Participate in Investor Conferences in May and June
-
Adagene to Participate in Investor Conferences in May and June
-
Adagene Inc. (ADAG) Presents Preclical Data Demonstrating First and Best-in-Class Potential for Antibody Candidates at AACR
-
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
-
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
